67 results about "LNCaP" patented technology

The invention discloses a miR-205 gene knockout kit based on CRISPR-Cas9 gene knockout technology. According to the invention, an optimal CRISPR-Cas9 target sequence of a certain amount of miR-205 is obtained through target design software and an sgRNA single chain is synthesized in vitro; an insertion fragment is obtained through processing; then sgRNA is inoculated into a plasmid vector by using T4 ligase; and a miR-205 gene knockout cell strain is obtained through transfection of an LNCap cell strain, continuous drug screening and fluorescence detection. Heterogenous hybridization double strands are obtained by extracting DNAs of a cell, PCR amplification of miR-205, purification, denaturation of a PCR product and annealing; T7E1 enzyme digestion test is employed to determining shearing efficiency of a CRISPR-Cas9 system on miR-205; a verified optimized a miR-205 gene knockout CRISPR-Cas9 target sequence is obtained; and the kit is constructed on the basis of the target sequence and can be used for directional knockout of miR-205 genes. The kit has the characteristics of high gene knockout efficiency, fast speed, easiness and economic performance and has wide prospects in the aspects of construction of animal models and clinical research of medical science.

A treatment for cancer using a combination therapy including an inhibitor of the PI3K/Akt pathway in combination with roscovitine. It is shown that the combination of roscovitine and API-2 (Triciribine) or roscovitine and LY294002 induce the apoptosis of androgen-dependent (LNCaP) and androgen-independent (PC3) prostate cancer cells. Two important results have been observed. First, cells that respond to roscovitine alone (LNCaP) initiate apoptosis sooner when co-treated. Second, cells that do not respond to roscovitine alone (PC3) apoptose when co-treated, although with delayed kinetics. In the absence of roscovitine, AKT inhibitors had no effect on LNCaP or PC3 survival, and in both cell lines, the combined treatment activated the mitochondrial pathway of apoptosis. Importantly, normal epithelial cells (RPWE) remained viable in the presence of roscovitine and AKT inhibitors. Events elicited by roscovitine (down-regulation of XIAP) and AKT inhibitors (accumulation of Bim) in LNCaP and PC3 cells are identified. Additional data show that PC3 cells apoptose when treated with AKT inhibitors and depleted of either XIAP or Cdk9. Taken together, these important results lead to improved treatments for cancers, such as prostate cancer, through the combination therapies taught herein.

Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein. Transfection of DU-145 and PC-3 cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 68% and 42%, respectively. Transfection of MDA-MB-231 and MDA-MB-435s cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 50% for either cell line. The prostasin gene promoter region was found to be hypermethylated at specific sites in invasive cancer cells.

The invention provides a single-chain antibody in an anti-human prostate-specific membrane antigen (PSMA) extracellular region, which adopts the phage display technology. The antibody is obtained by screening and enriching a large-storage capacity single-chain antibody library which is established by using peripheral blood mono-nuclear cells of a prostatic cancer patient through successive relaxation and rigorousness. The antibody can be solubly expressed in colon bacillus, and the affinity of the antibody with the prostate-specific membrane antigen extracellular region reaches Kd of 0.2nM. The antibody not only can be combined with the recombinant PSMA extracellular region, but also can be combined with NEK 293 cells with PSMA expressed on surface thereof and a prostate adenocarcinoma cell LNCaP, thus laying a foundation for adopting the antibody to perform prostate adenocarcinoma image diagnosis and guiding treatment.

The invention relates to the field of traditional Chinese medicine extract, and particularly discloses application of tripterygium wilfordii root extract triptophenolide (CAS number:74285-86-2) as an androgen receptor antagonist and application of triptophenolide to preparation of drugs for treating androgen disorders and drugs for male contraception. A reliable androgen activity screening method is constructed, the inhibiting effect of various kinds of traditional Chinese medicine extract on androgen receptor activity is tested, and finally it is found that the tripterygium wilfordii root extract triptophenolide is a novel androgen receptor antagonist and can inhibit activity of wild type and mutability androgen receptors. Further, anti-prostrate-cancer activity of triptophenolide is tested, and it is found that triptophenolide has good activity for AR (androgen receptor) positive prostrate cancer cells such as LNCaP and 22 RV1.

The invention discloses a toad lactam compound as well as a preparation method and application thereof. The preparation method comprises the steps of: mixing a toad lactone compound and ammonium acetate according to molar ratio of 1: (3-8); dissolving by utilizing organic solvent; reacting at a temperature of 100-160 DEG C for 0.5-3h under the protection of inert gas; decompressing, concentrating, removing the organic solvent; separating and purifying by utilizing a preparative high performance liquid chromatography method; and obtaining the toad lactam compound. The preparation method is simple, easy to carry out, safe, reliable and higher in yield. Proved by experiments, the toad lactam compound obtained in the invention has the advantages of good antitumor effect, very strong inhibitory action on various cancer cells such as PC3, DU145, LNCaP, MCF-7 and Hela, especially much better selective inhibitory action to hormone-dependent cancer cells such as the LNCaP and the MCF-7 than the toad lactone compound and remarkably lower toxicity to normal cells than the toad lactone compound. The toad lactam compound applied in preparing antitumor drugs has the advantages of being high in efficiency and low in toxicity and meeting the requirements of drug development.

The invention discloses an application of N-heteroaryl phenylamine compounds for preparation of antitumor drugs; the N-heteroaryl phenylamine compounds are represented by the general formula I, wherein in the formula, definitions of all substituents are shown in the description. The compounds represented by the general formula (I) have good antitumor activity, and especially have excellent activity on lung cancer A549 and H460, bladder cancer T24 and J82, prostatic cancer LNCap and PC-3 and the like.

The invention discloses application of a bixanthone compound FLBG-1108 or its medicinal salt in preparing anticancer medicaments. The invention, by means of experiments, finds that the bixanthone compound FLBG-1108 has an obvious inhibition effect on propagation of human non-small cell lung cancer H520, A549, H549, 1299, human breast cancer cell MCF7, human prostatic cancer cell PC3, LNcaP, DU145, as well as human intestinal cancer cell SW480 and HT-2P, can selectively inhibit the propagation of the human lung cancer cell H520, and presents good time and concentration dependence. After 48h of action, the IC50 value is 2.90 micrometers, which shows no cytotoxicity to a normal kidney epidermal cell. Further, the bixanthone compound FLBG-1108 is found to play an effective role in inducing apoptosis of the lung cancer cell H520, preventing propagation of cancer cells but showing no toxicity, and can specifically block the cell cycle of the lung cancer cell H520 in S stage, thus inhibiting the propagation of cancer cells. Therefore, the bixanthone compound FLBG-1108 can be developed into novel candidate medicaments with an anticancer effect, especially an anti-lung cancer effect.

The invention belongs to the field of medical care detection, and particularly relates to a molecular probe APT10-3.2-MZF-NPs for diagnosing prostatic cancer and a preparation method of the molecularprobe APT10-3.2-MZF-NPs. The probe is prepared by coupling an aptamer A10-3.2 with manganese-zinc ferrite nanoparticles. The APT10-3.2-MZF-NPs molecular probe has specificity targeting on prostatic cancer LNCaP cells, can pass MR detection, and is hopeful to become a novel targetting contrast to be used for MR molecular imaging.

The invention discloses six triterpenoid compounds separated from the vaccaroside, namely, vaccaroside I, vaccaroside E, vaccaroside G, vaccaroside B, segetoside H and segetoside I. The in-vitro antitumor tests show that the compounds have obvious inhibitory effect on LNcap, P-388 and A-549 cell lines and provide a new ides on the development of new anti-cancer drugs and have great value on the deep development of traditional Chinese medicine resources.

This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu and correlates to amino acid no. 300-309 of fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LD₅₀ of 0.3-0.4 μM, while the LD₅₀ for zinc-charged fetuin is 3-10 μM.

The invention discloses new use of a cell line LNCaP and a cell line C4-2. The new use is the use of the cell line LNCaP and the cell line C4-2 in the preparation of a prostate cancer cell model which is sensitive to radiation and generates resistance to the radiation. The new use of the cell line LNCaP and the cell line C4-2 demonstrates a new characteristic, namely the resistance of theC4-2 cells to ionizing radiation, of the LNCaP/C4-2 cell model first, and the LNCaP/C4-2 may be the cell model which represents the prostate cancer cells developing from IR sensitivity into IR resistance. The new use of the cell line LNCaP and the cell line C4-2 can be used for selecting an ionizing radiation induced gene which determines that the prostate cancer cells developing from the radiation sensitivity into the radiation resistance so as to select relative genes which take part in and determine the progression of the prostatic cancer, and thus, the first stone for discovering more effective clinic therapeutic target with hormone resistance and radiation resistance is laid.

The invention discloses an application of a phenyl ether compound as shown in general formula I in preparation of antitumor drugs. The compound of the general formula I has very good antitumor activity, and especially has excellent activity for human bladder cancer LNCap, T24, J82 and human prostate cancer PC-3.

The invention provides hTERT gene antisense oligodeoxynucleotide, a drug composition and application, belonging to the technical field of gene drugs. The sequence of the antisense oligodeoxynucleotide is 5minute-GGAGCGCGCGGCATCGCGGG-3minute. After hTERT gene total phosphorothioate modified antisense oligodeoxynucleotide (AS PS-ODN) inhibits flutamide tolerance type prostate cancer cell LNCaP-flu telomerase activity, a Tibetan drug, i.e., dry whole grass of O. Falcata Bunge has a sensibilization effect on LNCaP-flu cell apoptosis.

The invention discloses a cell culture plate coated with Matrigel as well as a preparation method and an application of the cell culture plate. A carboxy surface is formed on the surface of a cell culture plate by adopting a plasma spraying technology, the Matrigel is connected to the surface of the polystyrene cell culture plate or culture dish in a form of a covalent bond by adopting a chemical riveting technology, and the cell culture plate or culture dish coated with the Matrigel is formed. Because a chemical combined surface treatment mode is adopted on the surface of a base material of the culture plate, the Matrigel on the surface is not dissolved. Compared with a physically coated cell culture plate, the cell culture plate has the advantage of long preservation time. The culture plate (dish) is applicable to culture of primary cells and a few cells which are difficult in attaching to walls, easily cluster, easily drop and are slow in growth such as neurons, LNCaP and PC-12; and by adopting the culture plate (dish), the cells attach to the walls firmly and extend fully, and a stable growth state is obtained.

The invention discloses an application of bixanthone compound FLBG-1108 or its pharmaceutical salts in the preparation of anti-cancer drugs. It is found in the invention through experiments that the bixanthone compound FLBG-1108 has an obvious inhibitory effect on the multiplication of human non-small cells lung cancer cells H520, A549, H549, 1299, a human breast cancer cell MCF7, human prostatic cancer cells PC3, LNcaP, and DU145 and human intestinal cancer cells SW480 and HT-2P. The multiplication of human lung cancer cells H520 can be inhibited selectively by the bixanthone compound FLBG-1108. The good time and the concentration dependence can be presented. The value of IC50 after 48 h action is 2.90 muM. The cytotoxicity is not expressed at this concentration on normal renal epidermal cells. Further, the bixanthone compound FLBG-1108 can effectively induce the apoptosis of lung cancer cells H520 and prevent the multiplication of cancer cells. Meanwhile, no toxicity will be presented. The bixanthone compound FLBG-1108 can specifically interdict the cell cycle of lung cancer cells H520 in S phase and can therefore inhibit the multiplication of cancer cells. Therefore, the bixanthone compound FLBG-1108 can be developed into a new candidate drug with an anti-cancer effect especially an anti-lung cancer effect.

The invention discloses diaryl substituted glycolythiourea compounds, the structure of which are shown in a formula (I), wherein R1 is hydrogen, halogen or trifluoromethyl; R2 is hydrogen, halogen, trifluoromethyl, nitrile or alkoxyl; R3 is hydrogen, halogen or nitrile; R4 is hydrogen or halogen; R5 is hydrogen, halogen, methyl, N-methylamine formyl, N-ethylamine formyl, N-isopropylamine formyl and N-cyclopropylamine formyl. The diaryl substituted glycolythiourea compounds disclosed by the invention, particularly 7b-7g, 7i-7k, 7m-7p and 7r-7t, have strong growth inhibiting activity to a hormone-dependent prostate cancer cell LNCaP and can be used for preparing anti-tumor medicines.

The invention discloses a bifunctional molecule as well as a preparation method and application thereof. The bifunctional molecule provided by the invention can inhibit proliferation of LNCap cells, and part of the compounds also have an effect of inhibiting proliferation of PC-3 cells, so that the bifunctional molecule provided by the invention has the potential of treating cancers, especially prostatic cancers. In addition, the preparation method of the bifunctional molecule is mild in condition, simple to operate, free of high-temperature and low-temperature extreme reaction conditions, free of high-risk and highly toxic substances, suitable for laboratory synthesis and industrial production and wide in industrial application prospect.

The present disclosure demonstrates the molecular effects of glyceollins on human prostate cancer cell LNCaP to further elucidate its potential effects on prostate cancer prevention. The glyceollins inhibited LNCaP cell growth similar to that of the soy isoflavone genistein. The growth inhibitory effects of the glyceollins appeared to be due to an inhibition on G1/S progression and correlated with an up-regulation of cyclin-dependent kinase inhibitor A1 and B1 mRNA and protein levels. By contrast, genistein only up-regulates cyclin-dependent kinase inhibitor A1. In addition, glyceollin treatments led to down-regulated mRNA levels for androgen responsive genes. In contrast to genistein, this effect of glyceollins on androgen responsive genes appeared to be mediated through modulation of an estrogen- but not androgen-mediated pathway. Hence, the glyceollins exerted multiple effects on LNCaP cells that may be considered cancer preventive and the mechanisms of action appeared to be different from other soy-derived phytochemicals.

The invention relates to applications of antagonist of aging related secreted factors, and a pharmaceutical composition for inhibiting castration-resistant prostate cancer. The aging related secreted factors are selected from MIP-3-alpha, RANTES, MCP-2 factors. The invention also provides applications of the aging related secreted factors to preparation of products for predicting prostate cancer prognosis, and the aging related secreted factors are selected from MIP-3-alpha, RANTES, and MCP-2 factors. The composition is advantageous in that based on discovery that MDV3100 can induce LNCaP FGC cells to generate cell aging, protein chips are employed to discover that MDV3100 can induce the LNCaP FGC cells to secrete a lot of chemotactic factors, such as MIP-3-alpha, RANTES, MCP-2 factors and the like, as well as SASP proteins, such as cytokine and the like, and a base is provided for subsequent researches, such as SASP and CRPC, prostate carcinoma with bone metastasis and the like.

The invention discloses application of zingiber strioatum volatile oil to preparation of anti-prostatic-cancer products and provides the application of the zingiber strioatum volatile oil to preparation of the anti-prostatic-cancer products. The zingiber strioatum volatile oil is especially suitable for the prostatic cancer caused by LNCaP and/or PC-3 cell pathological change; the IC50 of zingiberstrioatum flour volatile oil to LNCaP is 55.75 ug/mL, and the IC50 of the zingiber strioatum flour volatile oil to the PC-3 is 77.17 ug/mL; and the IC50 of zingiber strioatum root cynomorium songaricum volatile oil to LNCaP is 91.37 ug/mL, and the IC50 of the zingiber strioatum root volatile oil to the PC-3 is 36.68 ug/mL. The zingiber strioatum flour volatile oil comprises the main components ofbeta-phellandrene, beta-pinene, alpha-humulene, alpha-pinene, cryptone, beta-elemene and beta-myrcene. The zingiber strioatum root volatile oil comprises the main components of (E,E)-geranyl linalool, beta-phellandrene, beta-pinene, alpha-humulene, beta-humulene and isolongifolol. The zingiber strioatum volatile oil has a very good inhibition effect on the migration of LNCaP and PC-3 cells.